ArticleJournal of thrombosis and thrombolysis2015
Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.
Article in Journal of thrombosis and thrombolysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Beyond Rebalanced Haemostasis: Haemostatic Phenotypes, Thrombin Generation, and Clinical Risk in Chronic Liver Disease.TH open : companion journal to thrombosis and haemostasis · 2026Review
- Portal Vein Thrombosis in Liver Cirrhosis: A Review of Risk Factors and Predictive Indicators.Journal of clinical and translational hepatology · 2025Review
- The etiology of chronic splanchnic vein thrombosis in adults: a two-center analysis.American journal of blood research · 2025Article
- Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review.Journal of clinical medicine · 2022Review
- Incident portal vein thrombosis in liver transplant recipients in New Zealand: Predictors of risk and validation of portal vein thrombosis risk index calculator.Frontiers in transplantation · 2022Article
- Nontumoral Portal Vein Thrombosis: A Challenging Consequence of Liver Cirrhosis.Journal of clinical and translational hepatology · 2020Review
- Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders.Journal of clinical medicine · 2020Article
- Development of a Model to Predict Portal Vein Thrombosis in Liver Transplant Candidates: The Portal Vein Thrombosis Risk Index.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2019Article
- Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta-analysis.Research and practice in thrombosis and haemostasis · 2019Article
- Anticoagulation in the cirrhotic patient.JHEP reports : innovation in hepatology · 2019Review
- Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate.World journal of gastroenterology · 2019Review
- Concise Commentary: The Clot Thickens-Why Pylephlebitis Is One of the Most Feared Complications of Intra-abdominal Sepsis.Digestive diseases and sciences · 2019Article
- Management of Non-tumoral Portal Vein Thrombosis in Patients with Cirrhosis.Digestive diseases and sciences · 2019Review
- Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference.Thrombosis and haemostasis · 2018Article
- Effects of Portal Vein Thrombosis on the Outcomes of Liver Cirrhosis: A Mexican Perspective.Journal of translational internal medicine · 2017Article
- Thrombin activation and liver inflammation in advanced hepatitis C virus infection.World journal of gastroenterology · 2016Review
- PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and Prothrombin 20210A in Splanchnic Vein Thrombosis: Analysis of Individual Patient Data From Three Prospective Studies.Journal of clinical and experimental hepatology · 2016Article
- Venous thromboembolism in patients with liver diseases.Internal and emergency medicine · 2015Article
- Portal Vein Thrombosis in Cirrhosis.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cirrhosis, myeloproliferative disorders (MPDs) and prothrombotic mutations are aetiologic factors for portal vein thrombosis (PVT). The role and frequency of thrombophilic genetic risk factors in cirrhotic patients is not well established. In this case-control study, we investigated the frequency of Janus kinase 2 (JAK2) (JAK2 V617F), Factor V Leiden (FVL G1691A), and Prothrombin (G20210A) mutations in cirrhotic patients with PVT (LCi+/PVT+ group, n = 21) in comparison with two control collectives (cirrhotic patients without PVT, LCi+/PVT- group, n = 43; PVT patients without liver cirrhosis, LCi-/PVT+ group, n = 29). In the LCi+/PVT+ group, JAK2 V617F was present in 2/21 patients (10 %; p = 0.104 compared to LCi+/PVT-; p = 0.092 compared to LCi-/PVT+), whereas 0/43 LCi+/PVT- patients (0 %; p < 0.001 compared to LCi-/PVT+) and 9/29 LCi-/PVT+ patients (31 %) harboured this mutation. The FVL G1691A mutation was identified in 1/21 patients (5 %) in the LCi+/PVT+ group, in 5/43 patients (12 %) in the LCi+/PVT- group, and in 2/29 patients (7 %) in the LCi-/PVT+ group. The Prothrombin G20210A mutation was present in 0/21 LCi+/PVT+ patients (0 %), in 1/43 LCi+/PVT- patients (2 %), and in 4/29 patients (14 %) in the LCi-/PVT+ group. This study provides evidence that a relevant proportion of cirrhotic patients with PVT harbours a JAK2 V617F mutation.
Indexed as
Identifiers
25115839What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.